Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.57
NAS:AMAG's Cash-to-Debt is ranked lower than
87% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:AMAG: 0.57 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AMAG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: No Debt Max: No Debt
Current: 0.57
Equity-to-Asset 0.38
NAS:AMAG's Equity-to-Asset is ranked lower than
80% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:AMAG: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AMAG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.86 Max: 0.99
Current: 0.38
0.33
0.99
Interest Coverage 0.43
NAS:AMAG's Interest Coverage is ranked lower than
98% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:AMAG: 0.43 )
Ranked among companies with meaningful Interest Coverage only.
NAS:AMAG' s Interest Coverage Range Over the Past 10 Years
Min: 0.43  Med: No Debt Max: No Debt
Current: 0.43
Piotroski F-Score: 4
Altman Z-Score: 0.55
Beneish M-Score: -2.92
WACC vs ROIC
3.76%
3.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 5.58
NAS:AMAG's Operating Margin % is ranked higher than
83% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:AMAG: 5.58 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AMAG' s Operating Margin % Range Over the Past 10 Years
Min: -4107.64  Med: -72.84 Max: 26.59
Current: 5.58
-4107.64
26.59
Net Margin % -5.61
NAS:AMAG's Net Margin % is ranked higher than
70% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:AMAG: -5.61 )
Ranked among companies with meaningful Net Margin % only.
NAS:AMAG' s Net Margin % Range Over the Past 10 Years
Min: -3696.96  Med: -71.06 Max: 109.19
Current: -5.61
-3696.96
109.19
ROE % -3.40
NAS:AMAG's ROE % is ranked higher than
75% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:AMAG: -3.40 )
Ranked among companies with meaningful ROE % only.
NAS:AMAG' s ROE % Range Over the Past 10 Years
Min: -52.39  Med: -15.27 Max: 42.96
Current: -3.4
-52.39
42.96
ROA % -1.27
NAS:AMAG's ROA % is ranked higher than
77% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:AMAG: -1.27 )
Ranked among companies with meaningful ROA % only.
NAS:AMAG' s ROA % Range Over the Past 10 Years
Min: -44.82  Med: -13.1 Max: 16.42
Current: -1.27
-44.82
16.42
ROC (Joel Greenblatt) % 136.69
NAS:AMAG's ROC (Joel Greenblatt) % is ranked higher than
97% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:AMAG: 136.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AMAG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1009.91  Med: -510.9 Max: 475.79
Current: 136.69
-1009.91
475.79
3-Year Revenue Growth Rate 60.80
NAS:AMAG's 3-Year Revenue Growth Rate is ranked higher than
89% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NAS:AMAG: 60.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:AMAG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -78.7  Med: 10.3 Max: 278.5
Current: 60.8
-78.7
278.5
3-Year EPS without NRI Growth Rate -45.80
NAS:AMAG's 3-Year EPS without NRI Growth Rate is ranked lower than
89% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:AMAG: -45.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:AMAG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51.7  Med: -8.15 Max: 100
Current: -45.8
-51.7
100
GuruFocus has detected 3 Warning Signs with AMAG Pharmaceuticals Inc $NAS:AMAG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AMAG's 30-Y Financials

Financials (Next Earnings Date: 2017-08-02 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

AMAG Guru Trades in Q2 2016

Steven Cohen 446,300 sh (New)
Joel Greenblatt 411,912 sh (+101.74%)
Paul Tudor Jones 375,500 sh (+31.20%)
» More
Q3 2016

AMAG Guru Trades in Q3 2016

Joel Greenblatt 507,809 sh (+23.28%)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
Q4 2016

AMAG Guru Trades in Q4 2016

Paul Tudor Jones 11,200 sh (New)
Jim Simons 513,500 sh (New)
Joel Greenblatt 600,584 sh (+18.27%)
» More
Q1 2017

AMAG Guru Trades in Q1 2017

Paul Tudor Jones 22,300 sh (+99.11%)
Jim Simons 766,000 sh (+49.17%)
Joel Greenblatt 678,918 sh (+13.04%)
» More
» Details

Insider Trades

Latest Guru Trades with AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ACRS, NAS:KERX, NAS:CYTK, NAS:ANIK, NAS:BYSI, NAS:VNDA, OTCPK:IPHYF, NAS:MGNX, NAS:ADRO, NAS:RVNC, NYSE:MYOV, NAS:CRSP, NAS:JNCE, NAS:ENTA, NAS:OMER, NAS:MESO, NAS:ACOR, NAS:AUPH, NAS:PRTK, NAS:EDIT » details
Traded in other countries:AMU.Germany,
Headquarter Location:USA
AMAG Pharmaceuticals Inc is a specialty pharmaceutical company with a focus on maternal health, anemia and cancer supportive care. The Company markets Makena; Feraheme, Injection for Intravenous (IV) use; and MuGard, Mucoadhesive Oral Wound Rinse.

Founded in 1981, AMAG Pharmaceuticals uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging.

Ratios

vs
industry
vs
history
Forward PE Ratio 3.36
AMAG's Forward PE Ratio is ranked higher than
98% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. AMAG: 3.36 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 5.03
AMAG's Price-to-Owner-Earnings is ranked higher than
91% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. AMAG: 5.03 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AMAG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.58  Med: 11.26 Max: 24.48
Current: 5.03
4.58
24.48
PB Ratio 0.70
AMAG's PB Ratio is ranked higher than
94% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. AMAG: 0.70 )
Ranked among companies with meaningful PB Ratio only.
AMAG' s PB Ratio Range Over the Past 10 Years
Min: 0.68  Med: 2.43 Max: 18.97
Current: 0.7
0.68
18.97
PS Ratio 1.17
AMAG's PS Ratio is ranked higher than
91% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. AMAG: 1.17 )
Ranked among companies with meaningful PS Ratio only.
AMAG' s PS Ratio Range Over the Past 10 Years
Min: 1.17  Med: 6.59 Max: 505.93
Current: 1.17
1.17
505.93
Price-to-Free-Cash-Flow 3.36
AMAG's Price-to-Free-Cash-Flow is ranked higher than
95% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. AMAG: 3.36 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AMAG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.34  Med: 20.54 Max: 1492.35
Current: 3.36
3.34
1492.35
Price-to-Operating-Cash-Flow 3.28
AMAG's Price-to-Operating-Cash-Flow is ranked higher than
94% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. AMAG: 3.28 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMAG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.26  Med: 20.45 Max: 1409.44
Current: 3.28
3.26
1409.44
EV-to-EBIT 30.64
AMAG's EV-to-EBIT is ranked higher than
57% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. AMAG: 30.64 )
Ranked among companies with meaningful EV-to-EBIT only.
AMAG' s EV-to-EBIT Range Over the Past 10 Years
Min: -787.3  Med: -5.6 Max: 87.5
Current: 30.64
-787.3
87.5
EV-to-EBITDA 7.46
AMAG's EV-to-EBITDA is ranked higher than
79% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. AMAG: 7.46 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMAG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -148.3  Med: -5.5 Max: 479.9
Current: 7.46
-148.3
479.9
Current Ratio 2.24
AMAG's Current Ratio is ranked lower than
69% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. AMAG: 2.24 )
Ranked among companies with meaningful Current Ratio only.
AMAG' s Current Ratio Range Over the Past 10 Years
Min: 1.65  Med: 10.02 Max: 62.43
Current: 2.24
1.65
62.43
Quick Ratio 2.12
AMAG's Quick Ratio is ranked lower than
68% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. AMAG: 2.12 )
Ranked among companies with meaningful Quick Ratio only.
AMAG' s Quick Ratio Range Over the Past 10 Years
Min: 1.4  Med: 9.78 Max: 61
Current: 2.12
1.4
61
Days Inventory 112.66
AMAG's Days Inventory is ranked higher than
52% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. AMAG: 112.66 )
Ranked among companies with meaningful Days Inventory only.
AMAG' s Days Inventory Range Over the Past 10 Years
Min: 112.66  Med: 441.37 Max: 1713.48
Current: 112.66
112.66
1713.48
Days Sales Outstanding 55.33
AMAG's Days Sales Outstanding is ranked lower than
52% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. AMAG: 55.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMAG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.4  Med: 49.36 Max: 581.14
Current: 55.33
27.4
581.14
Days Payable 22.05
AMAG's Days Payable is ranked lower than
85% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. AMAG: 22.05 )
Ranked among companies with meaningful Days Payable only.
AMAG' s Days Payable Range Over the Past 10 Years
Min: 11.5  Med: 130.3 Max: 2881.25
Current: 22.05
11.5
2881.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.40
AMAG's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. AMAG: -16.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMAG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -28.7  Med: -6.3 Max: 0.7
Current: -16.4
-28.7
0.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.44
AMAG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
94% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. AMAG: 0.44 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMAG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 6.42 Max: 96.83
Current: 0.44
0
96.83
Price-to-Median-PS-Value 0.18
AMAG's Price-to-Median-PS-Value is ranked higher than
91% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. AMAG: 0.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMAG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.57 Max: 277.17
Current: 0.18
0
277.17
Earnings Yield (Greenblatt) % 3.26
AMAG's Earnings Yield (Greenblatt) % is ranked higher than
86% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. AMAG: 3.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMAG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.1  Med: 3.55 Max: 6.6
Current: 3.26
1.1
6.6

More Statistics

Revenue (TTM) (Mil) $562.3
EPS (TTM) $ -0.95
Beta0.78
Short Percentage of Float30.28%
52-Week Range $17.90 - 36.83
Shares Outstanding (Mil)35.05

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 640 585 647
EPS ($) 5.51 2.47 2.97
EPS without NRI ($) 5.51 2.47 2.97
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AMAG

Headlines

Articles On GuruFocus.com
AMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs May 16 2017 
AMAG Pharmaceuticals Completes Financing Transactions in Support of Future Growth Strategy May 15 2017 
AMAG Pharmaceuticals to Host Analyst Day on May 24th in New York May 10 2017 
AMAG Pharmaceuticals Announces Pricing of $300 Million of 3.25% Convertible Senior Notes Due 2022 May 05 2017 
AMAG Pharmaceuticals Announces Proposed Offering of $250 Million of Convertible Senior Notes due 202 May 03 2017 
AMAG Announces Positive Topline Data From Phase 3 Feraheme® (ferumoxytol) Label Expansion Study May 02 2017 
AMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference Apr 26 2017 
AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance Apr 25 2017 
AMAG Pharmaceuticals to Host First Quarter 2017 Financial Results Conference Call and Webcast on Tue Apr 19 2017 
AMAG Submits Supplemental New Drug Application to FDA for Makena® (Hydroxyprogesterone Caproate I Apr 17 2017 

More From Other Websites
AMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs May 16 2017
Alpha & Omega Semiconductor, AMAG Pharmaceuticals and Trade Desk highlighted as Zacks Bull and Bear... May 15 2017
AMAG Pharmaceuticals Completes Financing Transactions in Support of Future Growth Strategy May 15 2017
Bear of the Day: AMAG Pharmaceuticals (AMAG) May 15 2017
AMAG Pharmaceuticals, Inc. -- Moody's upgrades AMAG's sr. notes to Ba3; affirms B2 CFR May 12 2017
What Makes AMAG Pharmaceuticals (AMAG) a Strong Sell? May 10 2017
AMAG Pharmaceuticals to Host Analyst Day on May 24th in New York May 10 2017
ETFs with exposure to AMAG Pharmaceuticals, Inc. : May 5, 2017 May 05 2017
AMAG Pharmaceuticals Announces Pricing of $300 Million of 3.25% Convertible Senior Notes Due 2022 May 05 2017
AMAG Pharmaceuticals, Inc. -- Moody's: AMAG's proposed refinancing credit positive May 04 2017
Edited Transcript of AMAG earnings conference call or presentation 2-May-17 12:00pm GMT May 04 2017
AMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 May 04 2017
AMAG Pharmaceuticals Announces Proposed Offering of $250 Million of Convertible Senior Notes due... May 03 2017
AMAG Pharma (AMAG) Incurs Loss in Q1, Revenues Rise Y/Y May 03 2017
Biotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals May 02 2017
AMAG Pharmaceuticals reports 1Q loss May 02 2017
AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update May 02 2017
AMAG Announces Positive Topline Data From Phase 3 Feraheme® (ferumoxytol) Label Expansion Study May 02 2017
Investor Network: AMAG Pharmaceuticals, Inc. to Host Earnings Call May 02 2017
AMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference Apr 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat